Ensysce Biosciences Inc
ENSC0.461USD
+0.002+0.52%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.47MMarket Cap
LossP/E TTM
More Details of Ensysce Biosciences Inc Company
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
Ensysce Biosciences Inc Info
Ticker SymbolENSC
Company nameEnsysce Biosciences Inc
IPO dateDec 01, 2017
CEOKirkpatrick (Lynn D)
Number of employees7
Security typeOrdinary Share
Fiscal year-endDec 01
Address7946 Ivanhoe Avenue, Suite 201
CityLA JOLLA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92037
Phone18582634196
Websitehttps://ensysce.com/
Ticker SymbolENSC
IPO dateDec 01, 2017
CEOKirkpatrick (Lynn D)
Company Executives of Ensysce Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew K. Benton, J.D.
Mr. Andrew K. Benton, J.D.
Independent Director
Independent Director
--
--
Mr. William H.C. Chang
Mr. William H.C. Chang
Independent Director
Independent Director
--
--
Ms. Lee M. Rauch
Ms. Lee M. Rauch
Independent Director
Independent Director
--
--
Bob G. Gower ,
Bob G. Gower ,
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Curtis Rosebraugh, M.D.
Dr. Curtis Rosebraugh, M.D.
Independent Director
Independent Director
--
--
Dr. Lynn D. Kirkpatrick, Ph.D.
Dr. Lynn D. Kirkpatrick, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Adam S. Levin, M.D.
Dr. Adam S. Levin, M.D.
Independent Director
Independent Director
--
--
Mr. Steve R. Martin
Mr. Steve R. Martin
Independent Director
Independent Director
--
--
Mr. David Carl Humphrey, CPA
Mr. David Carl Humphrey, CPA
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
--
--
Mr. Geoffrey Birkett
Mr. Geoffrey Birkett
Chief Commercial Officer
Chief Commercial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew K. Benton, J.D.
Mr. Andrew K. Benton, J.D.
Independent Director
Independent Director
--
--
Mr. William H.C. Chang
Mr. William H.C. Chang
Independent Director
Independent Director
--
--
Ms. Lee M. Rauch
Ms. Lee M. Rauch
Independent Director
Independent Director
--
--
Bob G. Gower ,
Bob G. Gower ,
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Curtis Rosebraugh, M.D.
Dr. Curtis Rosebraugh, M.D.
Independent Director
Independent Director
--
--
Dr. Lynn D. Kirkpatrick, Ph.D.
Dr. Lynn D. Kirkpatrick, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Feb 6
Updated: Fri, Feb 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Perceptive Advisors LLC
2.45%
Adage Capital Management, L.P.
2.11%
DRW Securities, LLC
1.95%
The Vanguard Group, Inc.
1.04%
Financial Plan, Inc
0.68%
Other
91.78%
Shareholders
Shareholders
Proportion
Perceptive Advisors LLC
2.45%
Adage Capital Management, L.P.
2.11%
DRW Securities, LLC
1.95%
The Vanguard Group, Inc.
1.04%
Financial Plan, Inc
0.68%
Other
91.78%
Shareholder Types
Shareholders
Proportion
Investment Advisor
4.47%
Hedge Fund
3.00%
Private Equity
2.45%
Investment Advisor/Hedge Fund
0.45%
Research Firm
0.41%
Venture Capital
0.31%
Individual Investor
0.29%
Other
88.62%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
30
224.46K
16.57%
--
2025Q3
33
224.46K
16.88%
+42.93K
2025Q2
32
179.15K
21.04%
-174.41K
2025Q1
30
353.15K
17.59%
+63.81K
2024Q4
34
140.82K
24.61%
-167.56K
2024Q3
37
161.44K
5.98%
+128.15K
2024Q2
36
33.28K
6.30%
+13.30K
2024Q1
37
19.98K
9.51%
+47.00
2023Q4
38
3.54K
12.10%
-15.91K
2023Q3
45
19.45K
15.18%
-15.28K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Perceptive Advisors LLC
86.67K
2.45%
--
--
Sep 30, 2025
Adage Capital Management, L.P.
74.71K
2.11%
--
--
Sep 30, 2025
DRW Securities, LLC
69.14K
1.95%
+69.14K
--
Sep 30, 2025
The Vanguard Group, Inc.
36.71K
1.04%
+34.33K
+1444.95%
Sep 30, 2025
Renaissance Technologies LLC
15.57K
0.44%
+15.57K
--
Sep 30, 2025
Citadel Advisors LLC
14.52K
0.41%
+14.52K
--
Sep 30, 2025
Virtu Americas LLC
14.22K
0.4%
+14.22K
--
Sep 30, 2025
Geode Capital Management, L.L.C.
13.03K
0.37%
+2.87K
+28.24%
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Dec 03, 2024
Merger
15→1
Dec 03, 2024
Merger
15→1
Dec 03, 2024
Merger
15→1
Dec 03, 2024
Merger
15→1
Mar 30, 2023
Merger
12→1
Mar 30, 2023
Merger
12→1
Date
Ex-dividend Date
Type
Ratio
Dec 03, 2024
Merger
15→1
Dec 03, 2024
Merger
15→1
Dec 03, 2024
Merger
15→1
Dec 03, 2024
Merger
15→1
Mar 30, 2023
Merger
12→1
Mar 30, 2023
Merger
12→1
Mar 30, 2023
Merger
12→1
Mar 30, 2023
Merger
12→1
Oct 27, 2022
Merger
20→1
Oct 27, 2022
Merger
20→1
View more
